Veradermics, Inc (MANE) · Oct 19, 2026 · Other events
Above the bar — All primary and secondary endpoints met; up to 36.4 hairs/cm² vs 6.6 placebo
Veradermics’ Phase 3 clinical trial clears both efficacy endpoints again, strengthening VDPHL01’s approval case while long-term safety remains ahead.
Veradermics is a late-stage, single-lead dermatology biotech building VDPHL01 into a potential oral treatment for pattern hair loss; the company already had positive male Study ‘302’ data, while confirmatory Study ‘304’ was the remaining male Phase 3 proof point.
Study ‘304’ cleared the core approval hurdle and reproduced the earlier trial. The 536-patient trial met both co-primary endpoints and all secondary endpoints with high statistical significance. 〔0〕 (Press release — Study ‘304’ topline results). Hair-count gains were 28.6 hairs/cm² with once-daily dosing and 36.4 hairs/cm² with twice-daily dosing, versus 6.6 hairs/cm² for placebo. (Study ‘304’ efficacy results). That is slightly below Study ‘302’ on once-daily dosing but above it on twice-daily dosing, making the important takeaway reproducibility rather than a dramatic new efficacy step.
| Study ‘304’ Part A | VDPHL01 QD | VDPHL01 BID | Placebo |
|---|---|---|---|
| Mean non-vellus hair-count increase at Month 6 | 28.6 hairs/cm² | 36.4 hairs/cm² | 6.6 hairs/cm² |
| “Improved” or “much improved” AAIRS response | 55.7% | 68.7% | 15.0% |
| Any improvement in hair coverage | 78.8% | 85.0% | 35.3% |
| Investigator-rated improved hair coverage | 78.4% | 82.7% | 38.9% |
The patient-visible result is strong, not merely statistically positive. More than half of patients in the once-daily arm and nearly seven in ten in the twice-daily arm reported “improved” or “much improved” hair coverage, compared with 15.0% on placebo. 〔1〕 (Study ‘304’ patient-reported outcomes). Separation from placebo appeared by Month 2, supporting the company’s intended profile of fast and consistent activity rather than a benefit visible only at the six-month endpoint. 〔2〕 (Study ‘304’ efficacy results).
Safety supports the efficacy story but is not fully de-risked. No treatment-related serious adverse events or cardiac-origin adverse events of special interest were observed. 〔3〕 (Study ‘304’ safety results). The main trade-off is dose-related hypertrichosis: 2.2% with once-daily dosing versus 9.0% twice daily, alongside overall treatment-emergent adverse-event rates of 42.1% and 42.9% versus 28.2% for placebo (Study ‘304’ adverse-event overview). The filing also makes clear that there have been no head-to-head studies against finasteride or other minoxidil formulations, so the apparent competitive advantage remains cross-trial rather than directly proven. 〔4〕 (Male pattern hair-loss treatment landscape).
The event advances VDPHL01 from a promising single-trial program to a repeatable male Phase 3 package. Directionally, positive efficacy was already known from Study ‘302’; what is new is confirmation in a second, larger registration-directed male study with consistent efficacy and no new major safety signal. The remaining business questions are regulatory execution, durability through 12 months, financing, and whether the safety profile holds as exposure expands. Study ‘302’ 12-month data are expected later in 2026, while the female Study ‘306’ readout is anticipated in the first half of 2027.
Bottom line: This is a meaningful upgrade to the clinical story: Study ‘304’ validates the efficacy signal and strengthens the case that VDPHL01 can support an approval filing in men. It does not yet establish regulatory approval, long-term safety, or superiority over existing treatments in a head-to-head trial.
Study 302 12-month data, later in 2026
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!